Advances in Bilosomal Drug Delivery Systems: Formulation Approaches and In Vitro Characterization for CNS Targeting
Abstract
In order to overcome the drawbacks of traditional dosage forms, sophisticated nano-vesicular drug delivery systems have been developed as a result of recent advancements in pharmaceutical sciences. Because of their improved stability, flexibility, and capacity to promote medication absorption across biological barriers, bilosomes have drawn a lot of attention. Comprising non-ionic surfactants or phospholipids, cholesterol, and bile salts, bilosomes are bile salt-stabilized vesicular carriers that offer protection against enzymatic degradation and challenging physiological circumstances. Bilosomes are appropriate for oral, transdermal, and central nervous system (CNS) medication administration because of these special qualities. With an emphasis on formulation techniques and in vitro characterisation criteria, this review offers a thorough and critical analysis of bilosomes. The impact of preparation methods and formulation ingredients on drug release behaviour, entrapment efficiency, surface charge, and vesicle size are emphasised. To shed light on bilosome performance, a variety of in vitro evaluation techniques are compiled, such as particle size analysis, zeta potential measurement, morphological investigations, and cellular uptake evaluations. The dopamine agonist pramipexole, which is frequently used to treat Parkinson's disease, is described as a model medication to show how bilosomes can be employed in CNS therapy. Pramipexole has serious delivery concerns due to its short half-life, limited brain penetration, and dose-related side effects. These issues may be resolved by employing nano-vesicular devices. Overall, this review highlights the promise of bilosomes as effective drug carriers that can improve therapeutic results, increase bioavailability, and open up new avenues for CNS-targeted drug delivery.
Keywords: Dosage form; bilosomes; drug delivery; formulation
Keywords:
Dosage form, bilosomes, drug delivery, formulationDOI
https://doi.org/10.22270/jddt.v16i7.7892References
1. Arunachalam A, Mani S. Stability studies: a review. Asian J Pharm Anal Med Chem. 2013;1:184–195.
2. Jain S, Indulkar A, Harde H, Agrawal AK. Oral mucosal immunization using gluco mannosylated bilosomes. J Biomed Nanotechnol. 2014;10:932–947. doi:10.1166/jbn.2014.1807
3. Williamson DE, Elia RVD, Roberts CW, Woods S. Method for the preparation of a pharmaceutical-vesicle formulation and associated products and uses. United States patent. 2022. DOI: Not applicable
4. Sanderson DJ. Transmucosal delivery device and method of manufacturing same. Canada patent. 2019. DOI: Not applicable
5. Ferro V. Preparation of non-ionic surfactant vesicles and variants. University of Strathclyde patent. 2018. DOI: Not applicable
6. Stojančević M, Pavlović N, Goločorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. Front Life Sci. 2013;7:112–122. doi:10.1080/21553769.2013.879404
7. Ammar HO, Mohamed MI, Tadros MI, Fouly AA. High frequency ultrasound mediated transdermal delivery of ondansetron hydrochloride employing bilosomal gel systems: Ex-vivo and in-vivo characterization studies. J Pharm Investig. 2020;50:613–624. doi:10.1007/s40005-019-00462-3
8. Gupta DK, Ahad A, Waheed A, Aqil M, Al-Jenoobi FI, Al-Mohizea AM. Bilosomes: A novel platform for drug delivery. In: Nayak AK, Hasnain MS, Aminabhavi TM, Torchilin VP, editors. Systems of Nanovesicular Drug Delivery. Cambridge (MA): Academic Press; 2022. p. 293–309. doi:10.1016/B978-0-12-819784-5.00008-4
9. Palekar-Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: Superior vesicular carriers. Curr Drug Ther. 2020;15:312–320. doi:10.2174/1574885515666200429113031
10. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19:2965–2974. doi:10.1016/S0264-410X(00)00529-3
11. Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: In vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res. 2019;29:73–85. doi:10.1080/08982104.2018.1460327
12. Mohsen AM, Asfour MHH, Salama AAA. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Dev Ind Pharm. 2017;43:2043–2054. doi:10.1080/03639045.2017.1361980
13. Premanand B, Prabakaran M, Kiener TK, Kwang J. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS ONE. 2013;8:e55536. doi:10.1371/journal.pone.0055536
14. Wang L, Huang X, Jing H, Ma C, Wang H. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG). Food Res Int. 2021;149:110631. doi:10.1016/j.foodres.2021.110631
15. Chen Y, Jiang Z, Xu J, Zhang J, Sun R, Zhou J, et al. Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. J Nanobiotechnol. 2021;19:230. doi:10.1186/s12951-021-00961-5
16. Elkomy MH, Alruwaili NK, Elmowafy M, Shalaby K, Zafar A, Ahmad N, et al. Surface-modified bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics. 2022;14:563. doi:10.3390/pharmaceutics14030563
17. Niu M, Lu Y, Hovgaard L, Guan P, Tan Y, Lian R, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265–272. doi:10.1016/j.ejpb.2012.02.007
18. Nemr AA, El Mahrouk G, Badie HA. A comprehensive review on bilosome: a nano-vesicular drug delivery system to enhance bioavailability of the drug through different routes of administration. Bull Pharm Sci Assiut Univ. 2024;47(1):41–64. doi:10.21608/bfsa.2023.233276.1888
19. Bilosomes as a versatile drug delivery system: preparation techniques and biomedical application. Rec Pharm Biomed Sci. 2024;8(3):67–86.
20. Nemr AA, El Mahrouk G, Badie HA. A comprehensive review on bilosomes: a nano-vesicular drug delivery system to enhance bioavailability through different routes of administration. Bull Pharm Sci. 2024;47(1):41–64. doi:10.21608/bfsa.2023.233276.1888
21. Abdelbary AA, El-Gendy NA. Niosomes and transfersomes as vesicular carriers for enhanced drug delivery: recent advances. Drug Deliv. 2022;29(1):3275-3292. doi:10.1080/10717544.2022.2137680.
22. Touitou E, Godin B. Ethosomes for skin delivery of drugs: advances and challenges. Adv Drug Deliv Rev. 2023;193:114677. doi:10.1016/j.addr.2022.114677.
23. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2022;13:915123. doi:10.3389/fphar.2022.915123.
24. Kumar R, Singh A. Bile salt-based nanovesicles (bilosomes) as emerging carriers for oral and CNS drug delivery. Pharmaceutics. 2025;17(2):215. doi:10.3390/pharmaceutics17020215.
25. Riccardi D, Baldino L, Reverchon E. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field. J Transl Med. 2024;22:339. doi:10.1186/s12967-024-05160-4.
26. Garg V, Singh H, Bimbrawh S, Singh SK, Gulati M, Vaidya Y, et al. Ethosomes and transfersomes: principles, perspectives and practices. Curr Drug Deliv. 2017;14(5):613-633. doi:10.2174/1567201813666160520114436.
27. Manchanda D, Makhija M, Pandey P, Sharma M. Transfersomes: recent advances, mechanisms, exhaustive applications, clinical trials, and patents. Curr Drug Deliv. 2025;22(2):215-230. doi:10.2174/0115672018295038240209055444.
28. Sharma B, Chauhan I. A review: bilosomes as nanocarriers. Curr Nanomed. 2024;14(3):178-187. doi:10.2174/0124681873274362231110055846.
29. Munir M, Zaman M, Waqar MA, Hameed H, Riaz T. A comprehensive review on transethosomes as a novel vesicular approach for drug delivery through transdermal route. J Liposome Res. 2024;34(1):203-218. doi:10.1080/08982104.2023.2221354.
30. Touitou E, Natsheh H. The evolution of emerging nanovesicle technologies for enhanced delivery of molecules into and across the skin. Pharmaceutics. 2024;16(2):267. doi:10.3390/pharmaceutics16020267.
31. Lombardo D, Kiselev MA, Caccamo MT. Lipid-based nanovesicular drug delivery systems. Nanomaterials (Basel). 2021;11(12):3391. doi:10.3390/nano11123391.
32. De la Presa P, Rueda T, Morales MP, Chichon FJ, Arranz R, Valpuesta JM, et al. Gold nanoparticles generated in ethosome bilayers, as revealed by cryo-electron-tomography. Langmuir. 2009;25(16):9096-9101. doi:10.1021/la9005907.
33. Sharma B, Chauhan I. A review: bilosomes as nanocarriers. Curr Nanomed. 2024;14(3):178-187. doi:10.2174/0124681873274362231110055846.
34. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm. 2003;29(9):1013-1026. doi:10.1081/DDC-120025458.
35. Manna JF, Ferro VA, Mullen AB, Tetley L, Mullen M, Carter KC, et al. Optimization of a lipid based oral delivery system containing A/Panama influenza hemagglutinin. Vaccine. 2004;22(19):2425-2429. doi:10.1016/j.vaccine.2003.11.064.
36. Shrivastava S, Dewangan SK, Shrivastava S. Advancements in smart vesicular carriers: a shift from lipoidal to non-lipoidal drug delivery systems. J Pharm Res Integr Med Sci. 2025;10:16-58.
37. Dirir AM, Ali A, Hachem M. Recent advancements in lipid nanoparticles-based phytoactives delivery systems for neurodegenerative diseases. Int J Nanomedicine. 2025;20:10279-10300. doi:10.2147/IJN.S498733.
38. Elkomy MH, Eid HM, Elmowafy M, Shalaby K, Zafar A, Abdelgawad MA, et al. Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. Drug Deliv. 2022;29(1):2694-2704. doi:10.1080/10717544.2022.2116782.
39. Fong SY, Bauer-Brandl A, Brandl M. Oral bioavailability enhancement through supersaturation: an update and meta-analysis. Expert Opin Drug Deliv. 2017;14(3):403-426. doi:10.1080/17425247.2016.1218465.
40. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20-22):2965-2974. doi:10.1016/S0264-410X(00)00532-6.
41. Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal MA, et al. Bile salt stabilized vesicles (bilosomes): a novel nano-pharmaceutical design for oral delivery of proteins and peptides. Curr Pharm Des. 2017;23(11):1575-1588. doi:10.2174/1381612823666170124111142.
42. Elebyary TT, Sultan AA, Abu-Risha SE, El Maghraby GM. Bilosomes as oral drug delivery carrier. J Adv Med Pharm Res. 2024;5(2):49-55. doi:10.21608/JAMPR.2024.282250.1065.
43. Mitrović D, Zaklan D, Đanić M, Stanimirov B, Stankov K. The pharmaceutical and pharmacological potential applications of bilosomes as nanocarriers for drug delivery. Molecules. 2025;30(5):1181. doi:10.3390/molecules30051181.
44. Aralelimath K, Sahoo J, Wairkar S. Dermal drug delivery via bilosomes: a synergistic integration for better therapeutic outcomes. J Microencapsul. 2024;41(8):818-831. doi:10.1080/02652048.2024.2423618.
45. Kaurav H, Kapoor DN, Upadhyay NK. Bilosomes in brain drug delivery. Ther Deliv. 2023;14(8):473-475. doi:10.4155/tde-2023-0049.
46. El-Sayed MM, Hussein AK, Sarhan HA. Bile salt stabilized nanovesicles as a promising drug delivery technology: a general overview and future perspectives. J Drug Deliv Sci Technol. 2023;79:104057. doi:10.1016/j.jddst.2022.104057.
47. Aralelimath K, Sahoo J, Wairkar S. Dermal drug delivery via bilosomes: a synergistic integration for better therapeutic outcomes. J Microencapsul. 2024;41(8):818-831. doi:10.1080/02652048.2024.2423618.
48. Kaurav H, Tripathi M, Kaur SD, Bansal A, Kapoor DN, Sheth S. Emerging trends in bilosomes as therapeutic drug delivery systems. Pharmaceutics. 2024;16(6):697. doi:10.3390/pharmaceutics16060697.
49. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012.
50. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286.
51. Palekar-Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: superior vesicular carriers. Curr Drug Ther. 2020;15:312-320. doi:10.2174/1574885515666200429113031.
52. Kecman S, Škrbić R, Badnjević Cengić A, Mooranian A, Al-Salami H, Mikov M, et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulation adjuvants. Technol Health Care. 2020;28:325-335. doi:10.3233/THC-209014.
53. Elnaggar YSR. Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. Int J Nanomedicine. 2015;10:3955-3971. doi:10.2147/IJN.S82549.
54. Imam SS, Gilani SJ, Zafar A, Jumah MNB, Alshehri S. Formulation of miconazole-loaded chitosan-carbopol vesicular gel: optimization to in vitro characterization, irritation, and antifungal assessment. Pharmaceutics. 2023;15:581. doi:10.3390/pharmaceutics15020581.
55. Karunakaran B, Gupta R, Patel P, Salave S, Sharma A, Desai D, et al. Emerging trends in lipid-based vaccine delivery: a special focus on developmental strategies, fabrication methods, and applications. Vaccines (Basel). 2023;11:661. doi:10.3390/vaccines11030661.
56. Abdel-Moneum R, Abdel-Rashid RS. Bile salt stabilized nanovesicles as a promising drug delivery technology: a general overview and future perspectives. J Drug Deliv Sci Technol. 2023;79:104057. doi:10.1016/j.jddst.2022.104057.
57. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 2008;11(1):59-66. doi:10.18433/J3K01M.
58. Shukla A, Singh B, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol. 2011;164(2B):820-827. doi:10.1111/j.1476-5381.2011.01452.x.
59. Shukla A, Katare OP, Singh B, Vyas SP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 2010;385(1-2):47-52. doi:10.1016/j.ijpharm.2009.10.027.
60. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20-22):2965-2974. doi:10.1016/S0264-410X(00)00532-6.
61. Mann JFS, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, et al. Enhanced immunogenicity of an oral influenza vaccine delivered in acid-resistant bilosomes. J Control Release. 2009;140(1):66-71. doi:10.1016/j.jconrel.2009.07.019.
62. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of bilosomes as novel vesicular carriers for oral drug delivery. Expert Opin Drug Deliv. 2016;13(12):1685-1699. doi:10.1080/17425247.2016.1218465.
63. El-Nabarawi MA, Teaima MH, Helal DA, Habib BA, Abd El-Hady SS. Bilosomes as a novel vesicular carrier for oral delivery of carvedilol: improved bioavailability and pharmacodynamic activity. AAPS PharmSciTech. 2016;17(6):1433-1444. doi:10.1208/s12249-016-0469-7.
64. Abdelbary AA, AbouGhaly MHH. Design and optimization of topical methotrexate loaded bilosomes for enhanced management of rheumatoid arthritis. Int J Pharm. 2024;652:123842. doi:10.1016/j.ijpharm.2024.123842.
65. Kamel AM, Hassan NF, Abdallah MH. Development and characterization of bile salt stabilized vesicles for transdermal drug delivery applications. J Drug Deliv Sci Technol. 2023;86:104689. doi:10.1016/j.jddst.2023.104689.
66. Hassan EE, Mahmoud DB, Salem HF. Recent advances in bilosomal nanocarriers: formulation characteristics and biomedical applications. Drug Deliv Transl Res. 2024;14(4):756-772. doi:10.1007/s13346-023-01389-y.
67. Ibrahim MM, Shehata TM, Habib BA. Bilosomes as promising lipid nanovesicles: physicochemical characterization and pharmaceutical applications. Pharmaceutics. 2024;16(2):233. doi:10.3390/pharmaceutics16020233.
68. Pires PC, Paiva-Santos AC, Veiga F. Liposome-derived nanosystems for the treatment of behavioral and neurodegenerative diseases: the promise of niosomes, transfersomes, and ethosomes for increased brain drug bioavailability. Pharmaceuticals (Basel). 2023;16(10):1424. doi:10.3390/ph16101424.
69. Cheng G, Liu Y, Ma R, Cheng G, Guan Y, Chen X, et al. Anti-Parkinsonian therapy: strategies for crossing the blood-brain barrier and nano-biological effects of nanomaterials. Nano Micro Lett. 2022;14:105. doi:10.1007/s40820-022-00847-z.
70. Hernández-Parra H, Cortés H, Avalos-Fuentes JA, Del Prado-Audelo ML, Florán B, Leyva-Gómez G. Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization. J Nanobiotechnology. 2022;20:413. doi:10.1186/s12951-022-01612-5.
71. Choudhary M, Chaurawal N, Barkat MA, Raza K. Proliposome-based nanostrategies: challenges and development as drug delivery systems. AAPS PharmSciTech. 2022;23(8):293. doi:10.1208/s12249-022-02443-1.
72. Sharma B, Chauhan I. A review: bilosomes as nanocarriers. Curr Nanomed. 2024;14(3):178-187. doi:10.2174/0124681873274362231110055846.
73. Nemr AA, El Mahrouk G, Badie HA. A comprehensive review on bilosome: a nano-vesicular drug delivery system to enhance bioavailability of the drug through different routes of administration. Bull Pharm Sci Assiut Univ. 2024;47(1):41-64. doi:10.21608/bfsa.2023.233276.1888.
74. Naveen, Prashar D, Gupta A. Advantages and therapeutic applications of drug delivery vesicles: bilosomes. Int J Pharm Pharm Sci. 2025;7(2):141-144. doi:10.33545/26647222.2025.v7.i2b.205.
75. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20-22):2965-2974. doi:10.1016/S0264-410X(00)00532-6.
76. Abd-Elal RM, Shamma RN, Rashed HM. Bilosomes as emerging vesicular systems for oral drug delivery: a review. Future J Pharm Sci. 2023;9:12. doi:10.1186/s43094-023-00472-8.
77. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of bilosomes as novel vesicular carriers for oral drug delivery. Expert Opin Drug Deliv. 2016;13(12):1685-1699. doi:10.1080/17425247.2016.1218465.
78. Abd-Elal RM, Shamma RN, Rashed HM. Bilosomes as emerging vesicular systems for oral drug delivery: a review. Future J Pharm Sci. 2023;9:12. doi:10.1186/s43094-023-00472-8.
79. Al-Mahallawi AM, Khowessah OM, Shoukri RA. Enhanced transdermal delivery of tenoxicam using bilosomes: fabrication, characterization and in vivo evaluation. J Liposome Res. 2015;25(1):1-11. doi:10.3109/08982104.2014.911861.
80. Mann JFS, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, et al. Enhanced immunogenicity of an oral influenza vaccine delivered in acid-resistant bilosomes. J Control Release. 2009;140(1):66-71. doi:10.1016/j.jconrel.2009.07.019.
81. Hosny KM, Aldawsari HM, Bahmdan RH, Sindi AM, Kurakula M, Alrobaian MM, et al. Development and optimization of bilosomes for enhanced ocular delivery of tacrolimus. Pharmaceutics. 2022;14(5):970. doi:10.3390/pharmaceutics14050970
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Ashmit , Sapna Rani , Rambabu Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.